Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 1/20 | 0.52 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | CCR3 | P51677 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | PLG | P00747 | 1/20 | 0.41 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.41 |
| ▸ | C1S | P09871 | 1/20 | 0.41 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7088226 | 0.93 | TBXAS1 (0.50) | TBXAS1HRH1CCR3KCNA3PRSS1 | |
| SCHEMBL74120 | 0.91 | TBXAS1 (0.54) | TBXAS1HRH1CCR3SMN1; SMN2SLC6A2 | |
| SCHEMBL7388461 | 0.87 | TBXAS1 (0.56) | TBXAS1HRH1CCR3KCNA3PRSS1 | |
| SCHEMBL688706 | 0.84 | TBXAS1 (0.54) | TBXAS1HRH1CCR3SMN1; SMN2CYP11B1 | |
| SCHEMBL535547 | 0.84 | TBXAS1 (0.49) | TBXAS1SMN1; SMN2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL10051067 | 0.83 | TBXAS1 (0.52) | TBXAS1HRH1CCR3SMN1; SMN2CYP11B1 | |
| SCHEMBL3903556 | 0.83 | TBXAS1 (0.52) | TBXAS1HRH1CCR3PRSS1F2 | |
| SCHEMBL690259 | 0.83 | TBXAS1 (0.52) | TBXAS1HRH1CCR3KCNA3PRSS1 | |
| SCHEMBL689001 | 0.83 | TBXAS1 (0.52) | TBXAS1HRH1CCR3SMN1; SMN2PRSS1 | |
| SCHEMBL1070542 | 0.83 | CYP11B1 (0.55) | TBXAS1HRH1CCR3CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050107468-A1 | Process for the preparation of an enantiomerically enriched thio compound | DSM IP ASSETS B.V. (NL) | 2005-05-19 | — | — | US | disclosed |
| EP-1453797-A1 | PROCESS FOR THE PREPARATION OF AN ENANTIOMERICALLY ENRICHED THIO COMPOUND | DSM IP Assets B.V. (NL) | 2004-09-08 | — | — | EP | disclosed |
| EP-1325908-A1 | Process for the preparation of an enantiomerically enriched thio compound | DSM N.V. (NL) | 2003-07-09 | — | — | EP | disclosed |
| WO-2003051827-A1 | PROCESS FOR THE PREPARATION OF AN ENANTIOMERICALLY ENRICHED THIO COMPOUND | DSM IP ASSETS B.V. (NL) | 2003-06-26 | — | — | WO | disclosed |
| US-20030008832-A1 | Method of inhibiting neoplastic cells with benzimidazole derivatives | OSI PHARMACEUTICALS, INC. | 2003-01-09 | — | — | US | disclosed |
| EP-0779887-B1 | NOVEL BENZIMIDAZOLE DERIVATIVES HAVING CGMP-PHOSPHODIESTERASE INHIBITING ACTIVITY | OTSUKA PHARMA CO LTD (JP) | 2001-05-23 | — | — | EP | disclosed |
| US-5998437-A | ARTERIOSCLEROSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1999-12-07 | — | — | US | disclosed |
| WO-1997003070-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES HAVING CGMP-PHOSPHODISTERASE INHIBITING ACTIVITY | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008832-A1 | Method of inhibiting neoplastic cells with benzimidazole derivatives | MKI67, CCNI, TMBIM6 | TBXAS1 987/4885HRH1 2169/4885CCR3 4500/4885 |
| US-20050107468-A1 | Process for the preparation of an enantiomerically enriched thio compound | SLC7A1, TCP1, TFRC | TBXAS1 1883/4885HRH1 749/4885CCR3 2584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.